These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 30226585)

  • 1. B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
    Pizon M; Schott DS; Pachmann U; Pachmann K
    Int J Oncol; 2018 Nov; 53(5):2289-2299. PubMed ID: 30226585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-like growth factor receptor I (IGF-IR) and vascular endothelial growth factor receptor 2 (VEGFR-2) are expressed on the circulating epithelial tumor cells of breast cancer patients.
    Pizon M; Zimon DS; Pachmann U; Pachmann K
    PLoS One; 2013; 8(2):e56836. PubMed ID: 23418605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The number of tumorspheres cultured from peripheral blood is a predictor for presence of metastasis in patients with breast cancer.
    Pizon M; Schott D; Pachmann U; Pachmann K
    Oncotarget; 2016 Jul; 7(30):48143-48154. PubMed ID: 27340862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer.
    Pizon M; Lux D; Pachmann U; Pachmann K; Schott D
    J Transl Med; 2018 Dec; 16(1):356. PubMed ID: 30547831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.
    Schott DS; Pizon M; Pachmann U; Pachmann K
    Oncotarget; 2017 Sep; 8(42):72755-72772. PubMed ID: 29069824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H3 promotes the proliferation, migration and invasiveness of cervical cancer cells and is an indicator of poor prognosis.
    Li Y; Zhang J; Han S; Qian Q; Chen Q; Liu L; Zhang Y
    Oncol Rep; 2017 Aug; 38(2):1043-1050. PubMed ID: 28627681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the clinical malignant phenotype of prostate cancer a result of a highly proliferative immune-evasive B7-H3-expressing cell population?
    Liu Y; Vlatkovic L; Sæter T; Servoll E; Waaler G; Nesland JM; Giercksky KE; Axcrona K
    Int J Urol; 2012 Aug; 19(8):749-56. PubMed ID: 22487487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H3 expression in ductal and lobular breast cancer and its association with IL-10.
    Liu C; Liu J; Wang J; Liu Y; Zhang F; Lin W; Gao A; Sun M; Wang Y; Sun Y
    Mol Med Rep; 2013 Jan; 7(1):134-8. PubMed ID: 23128494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.
    Kim GE; Kim NI; Park MH; Lee JS
    Tumour Biol; 2018 Nov; 40(11):1010428318815032. PubMed ID: 30486739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of combined expression of B7-H3 and B7-H4 as prognostic marker in esophageal cancer patients.
    Chen L; Xie Q; Wang Z; Shi L; Wu C; Jiang J
    Oncotarget; 2016 Nov; 7(47):77237-77243. PubMed ID: 27764786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients.
    Maeda N; Yoshimura K; Yamamoto S; Kuramasu A; Inoue M; Suzuki N; Watanabe Y; Maeda Y; Kamei R; Tsunedomi R; Shindo Y; Inui M; Tamada K; Yoshino S; Hazama S; Oka M
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4(Suppl 4):S546-54. PubMed ID: 24562936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.
    Mao Y; Li W; Chen K; Xie Y; Liu Q; Yao M; Duan W; Zhou X; Liang R; Tao M
    Oncotarget; 2015 Feb; 6(5):3452-61. PubMed ID: 25609202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.
    Al-Sukaini A; Hornicek FJ; Peacock ZS; Kaban LB; Ferrone S; Schwab JH
    Clin Orthop Relat Res; 2017 Dec; 475(12):3071-3081. PubMed ID: 28725958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis.
    Brunner A; Hinterholzer S; Riss P; Heinze G; Brustmann H
    Gynecol Oncol; 2012 Jan; 124(1):105-11. PubMed ID: 21982044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.
    Benzon B; Zhao SG; Haffner MC; Takhar M; Erho N; Yousefi K; Hurley P; Bishop JL; Tosoian J; Ghabili K; Alshalalfa M; Glavaris S; Simons BW; Tran P; Davicioni E; Karnes RJ; Boudadi K; Antonarakis ES; Schaeffer EM; Drake CG; Feng F; Ross AE
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):28-35. PubMed ID: 27801901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epithelial and tumor-associated endothelial expression of B7-H3 in cervical carcinoma: relation with CD8+ intraepithelial lymphocytes, FIGO stage, and phosphohistone H3 (PHH3) reactivity.
    Brustmann H; Igaz M; Eder C; Brunner A
    Int J Gynecol Pathol; 2015 Mar; 34(2):187-95. PubMed ID: 25675190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells.
    Arigami T; Uenosono Y; Hirata M; Yanagita S; Ishigami S; Natsugoe S
    Cancer Sci; 2011 May; 102(5):1019-24. PubMed ID: 21251161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H3-mediated tumor immunology: Friend or foe?
    Wang L; Kang FB; Shan BE
    Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer.
    Jin Y; Zhang P; Li J; Zhao J; Liu C; Yang F; Yang D; Gao A; Lin W; Ma X; Sun Y
    Int J Clin Exp Pathol; 2015; 8(11):13987-95. PubMed ID: 26823710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.